The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Novartis Europharm LimitedEU/1/98/066/013

Main Information

Trade NameExelon
Active SubstancesRivastigmine hydrogen tartrate
Dosage FormOral solution
Licence HolderNovartis Europharm Limited
Licence NumberEU/1/98/066/013

Group Information

ATC CodeN06DA Anticholinesterases
N06DA03 rivastigmine


License statusAuthorised
Licence Issued
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing Status


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back